NetraMark Holdings Inc. (AIAI) Opens the Market

Toronto, Ontario--(Newsfile Corp. - May 5, 2026) - George Achilleos, Chief Executive Officer, NetraMark Holdings Inc. ("NetraMark", or the "Company") (TSX: AIAI) and their executive team, joined Dani Lipkin, Managing Director, Global Innovation Sector, Toronto Stock Exchange ("TSX"), to open the market to celebrate the Company's new listing on TSX. Cannot view this video? Visit: https://www.youtube.com/watch?v=p5-v_eWuXe8 NetraMark, headquartered in Toronto, ON, develops advanced AI technology for the pharmaceutical industry to help de-risk clinical trials and enable more informed late-phase decision-making. Its flagship product, NetraAI, is purpose-built to analyze small, complex clinical trial datasets to uncover treatment signals, meaningful patient populations, and distinct disease subtypes not captured by conventional analysis methods. Rather than forcing patients into predefined categories, NetraAI discovers underlying response structure and the patient subgroups associated with drug sensitivity, helping teams better understand which patients are more likely to benefit from treatment. NetraMark supports clinical development teams with clearer insights, more targeted patient-to-treatment matching, and precision analytics to optimize trial design and improve decision-making across therapeutic development. MEDIA CONTACT: Swapan Kakumanu CFO [email protected] 403-681-2549 Adam Peeler Investor Relations [email protected] 416-427-1235 To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295980